NEWS

Inspiring New Stories

Halozyme provides disruptive drug delivery solutions with the goal of improving patient experiences and outcomes that can enhance the competitiveness of emerging and established therapies. To catch up on our latest news, updates and Industry Insights, please review the links below:

Press Releases

Mahesh Krishnan Elected to Halozyme's Board of Directors

04/25/2024

Halozyme to Report First Quarter 2024 Financial and Operating Results

04/23/2024

Halozyme to Participate in Upcoming Investor Conferences

02/27/2024

HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS

02/20/2024

Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results

02/08/2024

Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

01/29/2024

Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis

01/18/2024

Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

01/16/2024

Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types

01/16/2024

Halozyme to Host Investor Business Forum and Long-Term Outlook Call

01/12/2024
View All Press Releases
All 3
All 3 /Company Updates 1 /Executive Insights 1 /Values Series 1

Insights Value Series: Introduction

April 5, 2022/by ehennes

Inspire Week – Highlighting the Importance of Recharging the Mind, Body and Spirit

August 9, 2021/by David Anderson

You’re A Small Biotech — How Should You Implement A Pharmacovigilance System?

January 28, 2021/by David Anderson

Press Releases

  • 05/21/21

    Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®

  • 05/10/21

    Halozyme Reports First Quarter 2021 Results

  • 04/29/21

    Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference

  • 04/20/21

    Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call

  • 02/24/21

    Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027

  • 02/23/21

    Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027

  • 02/23/21

    Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results

  • 02/10/21

    Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call

  • 01/15/21

    Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis

  • 01/11/21

    Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth

  • 01/04/21

    Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference

Copyright© 2015-2024. Halozyme, Inc. All rights reserved. All trademarks belong to their respective owners.